These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9614724)

  • 21. Betaseron for multiple sclerosis. Implications for therapeutics.
    Rudick RA
    Arch Neurol; 1994 Feb; 51(2):125-8. PubMed ID: 8304836
    [No Abstract]   [Full Text] [Related]  

  • 22. [Immunotherapy of multiple sclerosis. Consensus and controversies].
    Hohlfeld R
    Nervenarzt; 1999 Apr; 70(4):297. PubMed ID: 10354989
    [No Abstract]   [Full Text] [Related]  

  • 23. High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis.
    Hartung HP
    Expert Opin Pharmacother; 2009 Feb; 10(2):291-309. PubMed ID: 19236200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does interferon beta cause initial exacerbation of multiple sclerosis?
    Rudge P; Miller D; Crimlisk H; Thorpe J
    Lancet; 1995 Mar; 345(8949):580. PubMed ID: 7776786
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunotherapy for MS: clinical aspects and trials.
    Ebers GC; Sibley WA; Paty DW
    Acta Neurol Scand Suppl; 1995; 161():54. PubMed ID: 7653246
    [No Abstract]   [Full Text] [Related]  

  • 26. Newer versus older treatments for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B; Cohen JA
    Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of interferon beta 1b for multiple sclerosis. Patients will put up with side effects because of their desire to beat the disease.
    Chellingsworth M
    BMJ; 1996 Nov; 313(7067):1263. PubMed ID: 8939140
    [No Abstract]   [Full Text] [Related]  

  • 28. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a.
    Mohr DC; Likosky W; Boudewyn AC; Marietta P; Dwyer P; Van der Wende J; Goodkin DE
    Mult Scler; 1998 Dec; 4(6):487-9. PubMed ID: 9987757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment.
    Blake G; Murphy S
    Neurology; 1997 Dec; 49(6):1747-8. PubMed ID: 9409387
    [No Abstract]   [Full Text] [Related]  

  • 31. Update on management and genetics of multiple sclerosis.
    Sadovnick AD
    J Neural Transm Suppl; 1997; 50():167-72. PubMed ID: 9120416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis.
    Gasperini C; Pozzilli C; Bastianello S; Koudriavtseva T; Galgani S; Millefiorini E; Paolillo A; Horsfield MA; Bozzao L; Fieschi C
    Neurology; 1998 Feb; 50(2):403-6. PubMed ID: 9484362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
    Petkau J; White R
    Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643
    [No Abstract]   [Full Text] [Related]  

  • 34. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple sclerosis therapy. A practical guide.
    van Oosten BW; Truyen L; Barkhof F; Polman CH
    Drugs; 1995 Feb; 49(2):200-12. PubMed ID: 7729328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Options for multiple sclerosis therapy.
    Cotton P
    JAMA; 1994 Nov; 272(18):1393. PubMed ID: 7933404
    [No Abstract]   [Full Text] [Related]  

  • 37. Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis.
    Murdoch D; Lyseng-Williamson KA
    BioDrugs; 2005; 19(5):323-5. PubMed ID: 16207073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple sclerosis.
    Noseworthy JH; Lucchinetti C; Rodriguez M; Weinshenker BG
    N Engl J Med; 2000 Sep; 343(13):938-52. PubMed ID: 11006371
    [No Abstract]   [Full Text] [Related]  

  • 40. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist.
    Pachner AR
    Neurology; 1997 Sep; 49(3):647-50. PubMed ID: 9305316
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.